ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation

Journal of Biological Chemistry

Volumn 287, Issue 3, 2012, Pages 1790-1800

  Roy, Gouriprasanna ^a   Placzek, Ekaterina ^a   Scanlan, Thomas S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEINS; BINDING ASSAYS; BIOGENIC AMINES; CELLULAR UPTAKE; EQUILIBRIUM DISSOCIATION CONSTANT; HUMAN SERUM; IN-VIVO; LIPOPROTEIN PARTICLES; LOW DENSITY LIPOPROTEINS; PLASMA PROTEIN; PROTEIN COMPONENTS; SEQUENCE ANALYSIS; THYROID HORMONES;

AFFINITY CHROMATOGRAPHY; BODY FLUIDS; DISSOCIATION; HORMONES; STOICHIOMETRY; TISSUE;

PROTEINS;

3 IODOTHYRONAMINE; APOLIPOPROTEIN B100; BIOGENIC AMINE; CARRIER PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN; THYROID HORMONE DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CELL SECRETION; CELL TRANSPORT; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISSOCIATION CONSTANT; HUMAN; HUMAN CELL; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ISOLATION; RAT; SEQUENCE ANALYSIS; STOICHIOMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEIN B-100; CARRIER PROTEINS; HEP G2 CELLS; HUMANS; PROTEIN BINDING; RATS; THYRONINES;

VERTEBRATA;

EID: 84855853750     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.275552     Document Type: Article

References (45)

1. Piehl, S., Hoefig, C. S., Scanlan, T. S., and Köhrle, J. (2011) Thyronamines. Past, present, and future. Endocr. Rev. 32, 64-80
2. Scanlan, T. S., Suchland, K. L., Hart, M. E., Chiellini, G., Huang, Y., Kruzich, P. J., Frascarelli, S., Crossley, D. A., Bunzow, J. R., Ronca-Testoni, S., Lin, E. T., Hatton, D., Zucchi, R., and Grandy, D. K. (2004) 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 10, 638-642 (Pubitemid 38796856)
3. Doyle, K. P., Suchland, K. L., Ciesielski, T. M., Lessov, N. S., Grandy, D. K., Scanlan, T. S., and Stenzel-Poore, M. P. (2007) Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked neuroprotection against stroke injury. Stroke 38, 2569-2576 (Pubitemid 47329639)
4. Klieverik, L. P., Foppen, E., Ackermans, M. T., Serlie, M. J., Sauerwein, H. P., Scanlan, T. S., Grandy, D. K., Fliers, E., and Kalsbeek, A. (2009) Central effects of thyronamines on glucose metabolism in rats. J. Endocrinol. 201, 377-386
5. Regard, J. B., Kataoka, H., Cano, D. A., Camerer, E., Yin, L., Zheng, Y. W., Scanlan, T. S., Hebrok, M., and Coughlin, S. R. (2007) Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion. J. Clin. Invest. 117, 4034-4043 (Pubitemid 350224112)
6. Braulke, L. J., Klingenspor, M., DeBarber, A., Tobias, S. C., Grandy, D. K., Scanlan, T. S., and Heldmaier, G. (2008) 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilization. J. Comp. Physiol. B 178, 167-177 (Pubitemid 351164900)
7. Scanlan, T. S. (2009) Minireview. 3-Iodothyronamine (T1AM). A new player on the thyroid endocrine team? Endocrinology 150, 1108-1111
8. Chiellini, G., Frascarelli, S., Ghelardoni, S., Carnicelli, V., Tobias, S. C., DeBarber, A., Brogioni, S., Ronca-Testoni, S., Cerbai, E., Grandy, D. K., Scanlan, T. S., and Zucchi, R. (2007) Cardiac effects of 3-iodothyronamine. A new aminergic system modulating cardiac function. FASEB J. 21, 1597-1608 (Pubitemid 46684861)
9. Saba, A., Chiellini, G., Frascarelli, S., Marchini, M., Ghelardoni, S., Raffaelli, A., Tonacchera, M., Vitti, P., Scanlan, T. S., and Zucchi, R. (2010) Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology 151, 5063-5073
10. Hoefig, C. S., Köhrle, J., Brabant, G., Dixit, K., Yap, B., Strasburger, C. J., and Wu, Z. (2011) Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J. Clin. Endocrinol. Metab. 96, 1864-1872
11. Robbins, J. (1976) Thyroxine-binding proteins. Prog. Clin. Biol. Res. 5, 331-355
12. Schussler, G. C. (1990) Thyroxine-binding proteins. Thyroid 1, 25-34
13. Schussler, G. C. (2000) The thyroxine-binding proteins. Thyroid 10, 141-149
14. Hart, M. E., Suchland, K. L., Miyakawa, M., Bunzow, J. R., Grandy, D. K., and Scanlan, T. S. (2006) Trace amine-associated receptor agonists. Synthesis and evaluation of thyronamines and related analogues. J. Med. Chem. 49, 1101-1112 (Pubitemid 43221656)
15. Schürer, H., Stembera, K., Knoll, D., Mayer, G., Blind, M., Förster, H. H., Famulok, M., Welzel, P., and Hahn, U. (2001) Aptamers that bind to the antibiotic moenomycin A. Bioorg. Med. Chem. 9, 2557-2563 (Pubitemid 32824158)
16. Brousseau, T., Clavey, V., Bard, J. M., and Fruchart, J. C. (1993) Sequential ultracentrifugation micromethod for separation of serum lipoproteins and assays of lipids, apolipoproteins, and lipoprotein particles. Clin. Chem. 39, 960-964 (Pubitemid 23166851)
17. Ståhlman, M., Davidsson, P., Kanmert, I., Rosengren, B., Borén, J., Fagerberg, B., and Camejo, G. (2008) Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J. Lipid Res. 49, 481-490 (Pubitemid 351213633)
18. Fu, T., Mukhopadhyay, D., Davidson, N. O., and Borensztajn, J. (2004) The peroxisome proliferator-activated receptor α (PPARα) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. J. Biol. Chem. 279, 28662-28669 (Pubitemid 38900149)
19. Wiesner, P., Leidl, K., Boettcher, A., Schmitz, G., and Liebisch, G. (2009) Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 50, 574 -585
20. Lynn, E. G., Siow, Y. L., Frohlich, J., Cheung, G. T., and O, K. (2001) Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-κB. Kidney Int. 60, 520 -532
21. Bietrix, F., Yan, D., Nauze, M., Rolland, C., Bertrand-Michel, J., Coméra, C., Schaak, S., Barbaras, R., Groen, A. K., Perret, B., Tercé, F., and Collet, X. (2006) Accelerated lipid absorption in mice overexpressing intestinal SRBI. J. Biol. Chem. 281, 7214-7219 (Pubitemid 43847488)
22. Aviram, M., Lund-Katz, S., Phillips, M. C., and Chait, A. (1988) The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoprotein B-100 with cells. J. Biol. Chem. 263, 16842-16848 (Pubitemid 18268867)
23. Aviram, M., Bierman, E. L., and Chait, A. (1988) Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells. J. Biol. Chem. 263, 15416-15422
24. Benvenga, S., and Robbins, J. (1990) Enhancement of thyroxine entry into low density lipoprotein (LDL) receptor-competent fibroblasts by LDL. An additional mode of entry of thyroxine into cells. Endocrinology 126, 933-941 (Pubitemid 20079505)
25. Goldstein, J. L., Basu, S. K., and Brown, M. S. (1983) Receptor-mediated endocytosis of low density lipoprotein in cultured cells. Methods Enzymol. 98, 241-260 (Pubitemid 14219888)
26. Manthey, K. C., Chew, Y. C., and Zempleni, J. (2005) Riboflavin deficiency impairs oxidative folding and secretion of apolipoprotein B-100 in HepG2 cells, triggering stress response systems. J. Nutr. 135, 978-982 (Pubitemid 40638294)
27. Stewart, B. J., Roede, J. R., Doorn, J. A., and Petersen, D. R. (2009) Lipid aldehyde-mediated cross-linking of apolipoprotein B-100 inhibits secretion from HepG2 cells. Biochim. Biophys. Acta 1791, 772-780
28. Adeli, K., and Sinkevitch, C. (1990) Secretion of apolipoprotein B in serum-free cultures of human hepatoma cell line, HepG2. FEBS Lett. 263, 345-348 (Pubitemid 20143024)
29. Maiyoh, G. K., Kuh, J. E., Casaschi, A., and Theriault, A. G. (2007) Cruciferous indole-3-carbinol inhibits apolipoprotein B secretion in HepG2 cells. J. Nutr. 137, 2185-2189 (Pubitemid 47529574)
30. Jonas, A., and Phillips, M. C. (2008) in Biochemistry of Lipids, Lipoproteins and Membranes (Vance, D. E., and Vance, J. E., eds), 5th Ed, pp. 485-506, Elsevier, New York
31. Havel, R. J., Eder, H. A., and Bragdon, J. H. (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34, 1345-1353
32. Miyakawa, M., and Scanlan, T. S. (2006) Synth. Commun. 36, 891-902
33. Benvenga, S., and Robbins, J. (1998) Thyroid hormone efflux from monolayer cultures of human fibroblasts and hepatocytes. Effect of lipoproteins and other thyroxine transport proteins. Endocrinology 139, 4311-4318 (Pubitemid 28513720)
34. Theriault, A., Ogbonna, G., and Adeli, K. (1992) Thyroid hormone modulates apolipoprotein B gene expression in HepG2 cells. Biochem. Biophys. Res. Commun. 186, 617-623
35. Wood, W. J., Geraci, T., Nilsen, A., DeBarber, A. E., and Scanlan, T. S. (2009) Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo. ChemBioChem 10, 361-365
36. Callow, M. J., Stoltzfus, L. J., Lawn, R. M., and Rubin, E. M. (1994) Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 91, 2130-2134 (Pubitemid 24092056)
37. Purcell-Huynh, D. A., Farese, R. V., Jr., Johnson, D. F., Flynn, L. M., Pierotti, V., Newland, D. L., Linton, M. F., Sanan, D. A., and Young, S. G. (1995) Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high fat diet. J. Clin. Invest. 95, 2246-2257
38. Qiu, S., Bergeron, N., Kotite, L., Krauss, R. M., Bensadoun, A., and Havel, R. J. (1998) Metabolism of lipoproteins containing apolipoprotein B in hepatic lipase-deficient mice. J. Lipid Res. 39, 1661-1668 (Pubitemid 28377931)
39. Beghin, L., Duhal, N., Poulain, P., Hauw, P., Lacroix, B., Lecerf, J. M., Bonte, J. P., Fruchart, J. C., and Luc, G. (2000) Measurement of apolipoprotein B concentration in plasma lipoproteins by combining selective precipitation and mass spectrometry. J. Lipid Res. 41, 1172-1176 (Pubitemid 30483023)
40. Benvenga, S., Gregg, R. E., and Robbins, J. (1988) Binding of thyroid hormones to human plasma lipoproteins. J. Clin. Endocrinol. Metab. 67, 6-16
41. Benvenga, S., Cahnmann, H. J., and Robbins, J. (1990) Localization of the thyroxine-binding sites in apolipoprotein B-100 of human low density lipoproteins. Endocrinology 127, 2241-2246 (Pubitemid 20381754)
42. Benvenga, S., Cahnmann, H. J., Rader, D., Kindt, M., and Robbins, J. (1992) Thyroxine binding to the apolipoproteins of high density lipoproteins HDL2 and HDL3. Endocrinology 131, 2805-2811
43. Scanlan, T. S. (2011) Endogenous 3-iodothyronamine (T1AM). More than we bargained for. J. Clin. Endocrinol. Metab. 96, 1674-1676
44. Ianculescu, A. G., Giacomini, K. M., and Scanlan, T. S. (2009) Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology 150, 1991-1999
45. Ianculescu, A. G., Friesema, E. C., Visser, T. J., Giacomini, K. M., and Scanlan, T. S. (2010) Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. Mol. Biosyst. 6, 1403-1410